Combination therapy before surgery for triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial tests adding an immunotherapy drug to standard chemotherapy before surgery for triple-negative breast cancer. The goal is to see if this combination works better than chemotherapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older with triple-negative breast cancer (meaning the cancer cells don't have receptors for estrogen, progesterone, or HER2).
- You have a tumor sample that can be tested for a protein called PD-L1.
- Your cancer is stage IIA to IIIC and has not spread to other parts of the body.
- You have not had chemotherapy or targeted therapy for advanced breast cancer before.
- You are in good overall health (ECOG score 0-2) and your major organs are working well.
- You are willing to use birth control during the study and for 8 weeks after the last treatment dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of stereotactic body radiation therapy (SBRT), chemotherapy, and an immunotherapy drug called AK104 given before surgery to treat triple-negative breast cancer. It aims to see if this approach can shrink tumors more effectively and help patients avoid a mastectomy.
This trial tests whether adding an immunotherapy drug (camrelizumab) to standard chemotherapy before surgery can improve outcomes for women with early-stage triple-negative breast cancer. The treatment is given before surgery to shrink tumors and may help prevent the cancer from coming back.
This trial tests a new immunotherapy combination with chemotherapy given before breast cancer surgery, to shrink the tumor and improve outcomes. It's for people with early-stage triple-negative breast cancer whose tumors are larger than 2 cm.
This trial tests a combination of an immunotherapy drug (QL1706) plus standard chemotherapy given before surgery to shrink triple-negative breast cancer. The goal is to see if this approach helps remove the tumor more completely.
This study tests giving a combination of chemotherapy and immunotherapy before surgery for early stage triple negative breast cancer. The goal is to see if this approach can improve treatment outcomes and reduce the chance of the cancer coming back.
This trial tests adding a probiotic (Lactobacillus johnsonii) to a combination of chemotherapy and immunotherapy for people whose advanced solid tumors have grown despite prior immunotherapy. The goal is to see if the probiotic helps the treatment work better.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.